Omar Nadeem, MD, discusses the integration of isatuximab-irfc in relapsed/refractory multiple myeloma.
Omar Nadeem, MD, clinical director, Myeloma Cellular Therapies Program, physician, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the integration of isatuximab-irfc (Sarclisa) in relapsed/refractory multiple myeloma.
Isatuximab is a CD38-directed monoclonal antibody that is FDA approved for use in various combinations for patients with relapsed/refractory multiple myeloma, says Nadeem. However, CD38-directed antibodies are being evaluated in earlier lines of therapy, including the frontline setting, for patients with multiple myeloma, Nadeem explains.
Patients with multiple myeloma are often refractory to a CD38-directed antibody in their first or second relapse, so how patients will respond to retreatment with a CD38-directed antibody remains unknown, Nadeem says. As such, that unknown hinders the utility of isatuximab-based combinations in practice, adds Nadeem.
Currently, high rates of deep responses and good tolerability have been observed with isatuximab in combination with pomalidomide (Pomalyst) and dexamethasone, as well as with carfilzomib (Kyprolis) and dexamethasone, Nadeem explains. Whether isatuximab is superior to daratumumab (Darzalex) remains unknown, but having 2 options for these patients is welcome, concludes Nadeem.